![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Preview
Results of recently completed and ongoing trials may change the thinking on how to treat atherosclerosis. For example, even faithful adherence to the American Heart Association step 2 diet may not halt progression of established coronary artery disease. Also, current goals of lipid-lowering therapy may be inadequate to reverse coronary artery narrowings. Dr Kahn describes studies that have used more drastic measures to control hyperlipidemia, the effects of these measures on coronary atherosclerosis, and clinical application of results.
Additional information
Notes on contributors
Joel K. Kahn
Joel K. Kahn, MD Dr Kahn is clinical assistant professor of medicine, University of Michigan Medical School, Ann Arbor; an attending cardiologist, William Beaumont Hospitals, Royal Oak and Troy, Michigan; and a staff member with Michigan Heart Group, Troy. His professional interests include prevention of coronary artery disease through risk-factor reduction and treatment with angioplasty and atherectomy.